Biggest changeTwelve Months Ended December 31, 2024 Total Foreign Exchange Rates Adjustments (1) Adjusted Local Currency Revenue Flavors & Extracts 7.1 % 0.0 % N/A 7.1 % Color 6.6 % (0.7 %) N/A 7.3 % Asia Pacific 11.2 % (1.8 %) N/A 13.0 % Total Revenue 6.9 % (0.5 %) N/A 7.4 % Operating Income Flavors & Extracts 10.6 % (0.2 %) 0.0 % 10.8 % Color 13.4 % (0.8 %) 0.0 % 14.2 % Asia Pacific 11.9 % (2.2 %) 0.0 % 14.1 % Corporate & Other (13.7 %) 0.0 % (42.4 %) 28.7 % Total Operating Income 23.6 % (1.0 %) 15.3 % 9.3 % Diluted Earnings per Share 33.0 % (1.4 %) 28.5 % 5.9 % Adjusted EBITDA 7.6 % (0.7 %) N/A 8.3 % (1) Adjustments consist of Portfolio Optimization Plan costs.
Biggest changeTwelve Months Ended December 31, 2025 Total Foreign Exchange Rates Adjustments (1) Adjusted Local Currency Revenue Flavors & Extracts (0.9%) 0.4% N/A (1.3%) Color 8.1% 0.7% N/A 7.4% Asia Pacific 3.5% 1.1% N/A 2.4% Total Revenue 3.5% 0.6% N/A 2.9% Operating Income Flavors & Extracts 3.8% 0.4% 0.0% 3.4% Color 18.2% 1.3% 0.0% 16.9% Asia Pacific 6.3% 2.5% 0.0% 3.8% Corporate & Other 20.2% 0.0% 14.8% 5.4% Total Operating Income 8.1% 1.4% (4.4%) 11.1% Diluted Earnings per Share 7.5% 1.4% (8.6%) 14.7% Adjusted EBITDA 10.9% 1.1% N/A 9.8% (1) Adjustments consist of Portfolio Optimization Plan costs.
Changes in estimates of future cash flows caused by items such as unforeseen events or changes in market conditions could negatively affect the reporting units’ fair value and result in an impairment charge. 27 Index Income Taxes The Company estimates its income tax expense in each of the taxing jurisdictions in which it operates.
Changes in estimates of future cash flows caused by items such as unforeseen events or changes in market conditions could negatively affect the reporting units’ fair value and result in an impairment charge. Income Taxes The Company estimates its income tax expense in each of the taxing jurisdictions in which it operates.
Goodwill Valuation The Company reviews the carrying value of goodwill annually utilizing several valuation methodologies, including a discounted cash flow model. The Company completed its annual goodwill impairment test under Accounting Standards Codification (ASC) 350, Intangibles – Goodwill and Other , in the third quarter of 2024.
Goodwill Valuation The Company reviews the carrying value of goodwill annually utilizing several valuation methodologies, including a discounted cash flow model. The Company completed its annual goodwill impairment test under Accounting Standards Codification (ASC) 350, Intangibles – Goodwill and Other , in the third quarter of 2025.
Note: Refer to table above for a reconciliation of these non-GAAP measures. 25 Index SEGMENT INFORMATION The Company determines its operating segments based on information utilized by its chief operating decision maker to allocate resources and assess performance.
Note: Refer to table above for a reconciliation of these non-GAAP measures. 26 Index SEGMENT INFORMATION The Company determines its operating segments based on information utilized by its chief operating decision maker to allocate resources and assess performance.
The non-cash charges in 2024 were primarily related to trial production runs that did not meet quality specifications and thus were disposed of, and the non-cash charges in 2023 reduced the carrying value of certain inventories, as they were determined to be excess.
The non-cash charges in 2025 reduced the carrying value of certain inventories, as they were determined to be excess, and the non-cash charges in 2024 were primarily related to trial production runs that did not meet quality specifications and thus were disposed.
Portfolio Optimization Plan costs are discussed under “Portfolio Optimization Plan” above and Note 15, Portfolio Optimization Plan, in the Notes to the Consolidated Financial Statements included in this report. Note: Earnings per share calculations may not foot due to rounding differences .
Portfolio Optimization Plan costs are discussed under “Portfolio Optimization Plan” above and Note 14, Portfolio Optimization Plan, in the Notes to the Consolidated Financial Statements included in this report. Note: Earnings per share calculations may not foot due to rounding differences .
The effective tax rates in both 2024 and 2023 were impacted by the release of valuation allowances related to net operating losses, changes in estimates associated with the finalization of prior year foreign and domestic tax items, audit settlements, the mix of foreign earnings, and the limited tax deductibility of costs related to the Portfolio Optimization Plan.
The effective tax rates in both 2025 and 2024 were impacted by the release of valuation allowances related to net operating losses (NOLs), changes in estimates associated with the finalization of prior year foreign and domestic tax items, audit settlements, the mix of foreign earnings, and the limited tax deductibility of costs related to the Portfolio Optimization Plan.
For a discussion of the year ended December 31, 2023, compared to the year ended December 31, 2022, please refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on February 22, 2024, which is incorporated herein by reference.
For a discussion of the year ended December 31, 2024, compared to the year ended December 31, 2023, please refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on February 19, 2025, which is incorporated herein by reference.
See Note 11, Income Taxes , in the Notes to Consolidated Financial Statements included in this report for additional information. 2024 2023 Rate before Portfolio Optimization Plan and discrete items 25.2 % 25.5 % Portfolio Optimization Plan impact 0.3 % 4.7 % Discrete items (2.1 %) (2.1 %) Reported effective tax rate 23.4 % 28.1 % The 2025 effective income tax rate is estimated to be between 24% and 26%.
See Note 11, Income Taxes , in the Notes to Consolidated Financial Statements included in this report for additional information. 2025 2024 Rate before Portfolio Optimization Plan and discrete items 26.2 % 25.2 % Portfolio Optimization Plan impact 1.2 % 0.3 % Discrete items (3.1 %) (2.1 %) Reported effective tax rate 24.3 % 23.4 % The 2026 effective income tax rate is estimated to be between 24% and 25%.
This section generally discusses the results of our operations for the year ended December 31, 2024, compared to the year ended December 31, 2023.
This section generally discusses the results of our operations for the year ended December 31, 2025, compared to the year ended December 31, 2024.
Inventory write-downs are recorded as the difference between the cost of inventory and its estimated market value. The Company recorded non-cash charges of $0.7 million and $3.1 million in 2024 and 2023, respectively, in Cost of Products Sold related to the Portfolio Optimization Plan.
Inventory write-downs are recorded as the difference between the cost of inventory and its estimated market value. The Company recorded non-cash charges of $4.3 million and $0.7 million in 2025 and 2024, respectively, in Cost of Products Sold related to the Portfolio Optimization Plan.
The following table summarizes the percentage change in the 2024 results compared to the 2023 results in the respective financial measures.
The following table summarizes the percentage change in the 2025 results compared to the 2024 results in the respective financial measures.
The decrease in net cash provided by operating activities in 2024 was primarily due to a decrease in the cash provided by accounts receivable, partially offset by a decrease in cash used for performance-based compensation payments (which are determined based on prior year performance) made during 2024 compared to 2023.
The decrease in net cash provided by operating activities in 2025 was primarily due to an increase in cash used by inventory and an increase in cash used for performance-based compensation payments (which are determined based on prior year performance) made during 2025 compared to 2024, partially offset by an increase in cash provided by accounts receivable.
Adjusted diluted earnings per share, which exclude the Portfolio Optimization Plan costs, were $3.00 in 2024 and $2.86 in 2023 (see discussion below regarding non-GAAP financial measures). Additional information on the results is included below. RESULTS OF OPERATIONS 2024 vs. 2023 Revenue Sensient’s revenue was approximately $1.6 billion and $1.5 billion in 2024 and 2023, respectively.
Adjusted diluted earnings per share, which exclude the Portfolio Optimization Plan costs, were $3.48 in 2025 and $3.00 in 2024 (see discussion below regarding non-GAAP financial measures). Additional information on the results is included below. RESULTS OF OPERATIONS 2025 vs. 2024 Revenue Sensient’s revenue was approximately $1.61 billion and $1.56 billion in 2025 and 2024, respectively.
Management has recorded valuation allowances to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized. As of December 31, 2024, the Company recorded gross deferred tax assets of $112.3 million with an associated valuation allowance of $29.7 million.
Management has recorded valuation allowances to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized. As of December 31, 2025, the Company recorded gross deferred tax assets of $133.9 million with an associated valuation allowance of $29.1 million.
In October 2017, the Board of Directors authorized the repurchase of up to three million shares. As of December 31, 2024, 1,732,981 shares were available to be repurchased under the existing authorization. The Company’s share repurchase program has no expiration date. These authorizations may be modified, suspended, or discontinued by the Board of Directors at any time.
As of December 31, 2025, 1,732,981 shares were available to be repurchased under the existing authorization. The Company’s share repurchase program has no expiration date. These authorizations may be modified, suspended, or discontinued by the Board of Directors at any time. There were no shares of Company stock repurchased in 2025 or 2024.
Flavors & Extracts segment operating income was $97.1 million in 2024 and $87.8 million in 2023, an increase of approximately 11%. Foreign exchange rates had an immaterial impact on segment operating income. The higher segment operating income was a result of higher operating income in Flavors, Extracts & Flavor Ingredients, partially offset by lower operating income in Natural Ingredients.
Flavors & Extracts segment operating income was $100.7 million in 2025 and $97.1 million in 2024, an increase of approximately 4%. Foreign exchange rates had an immaterial impact on segment operating income. The higher segment operating income was a result of higher operating income in Flavors, Extracts & Flavor Ingredients, partially offset by lower operating income in Agricultural Ingredients.
In conducting its annual test for impairment, the Company performed a qualitative assessment of its previously calculated fair values for each of its reporting units. Fair value is estimated using both a discounted cash flow analysis and an analysis of comparable company market values. If the fair value of a reporting unit exceeds its net book value, no impairment exists.
In conducting its annual test for impairment, the Company performed a quantitative assessment of the fair values for each of its reporting units and compared each of these values to the net book value of each reporting unit. Fair value is estimated using both a discounted cash flow analysis and an analysis of comparable company market values.
The Company’s three reporting units each had goodwill recorded and were tested for impairment. All three reporting units had fair values that were above their respective net book values by at least 75%.
If the fair value of a reporting unit exceeds its net book value, no impairment exists. The Company’s three reporting units each had goodwill recorded and were tested for impairment. All three reporting units had fair values that were above their respective net book values by at least 75%.
The Company’s diluted earnings per share were $2.94 in 2024 and $2.21 in 2023. 2024 results were negatively impacted by $6.6 million ($2.5 million after tax, $0.06 per share) of Portfolio Optimization Plan costs. 2023 results were negatively impacted by $27.8 million ($27.4 million after tax, $0.65 per share) of Portfolio Optimization Plan costs.
The Company’s diluted earnings per share were $3.16 in 2025 and $2.94 in 2024. 2025 results were negatively impacted by $15.8 million ($13.8 million after tax, $0.32 per share) of Portfolio Optimization Plan costs. 2024 results were negatively impacted by $6.6 million ($2.5 million after tax, $0.06 per share) of Portfolio Optimization Plan costs.
LIQUIDITY AND FINANCIAL POSITION Financial Condition The Company’s financial position remains strong. The Company is in compliance with its loan covenants calculated in accordance with applicable agreements as of December 31, 2024.
See the Portfolio Optimization Plan section above for further information. LIQUIDITY AND FINANCIAL POSITION Financial Condition The Company’s financial position remains strong. The Company is in compliance with its loan covenants calculated in accordance with applicable agreements as of December 31, 2025.
The Company’s estimate of liabilities and related insurance recoveries may change as further facts and circumstances become known.
The Company recognizes related insurance reimbursement when receipt is deemed probable. The Company’s estimate of liabilities and related insurance recoveries may change as further facts and circumstances become known.
The higher operating income in Flavors, Extracts & Flavor Ingredients was primarily due to lower raw material costs, higher selling prices, higher volumes, and a favorable product mix. The lower operating income in Natural Ingredients was primarily due to higher raw material costs, partially offset by higher volumes and selling prices.
The higher operating income in Flavors, Extracts & Flavor Ingredients was primarily due to higher selling prices and volumes, partially offset by higher manufacturing and other costs.
The higher operating income in Personal Care was primarily due to higher volumes and selling prices and a favorable product mix. The higher operating income in Food & Pharmaceutical Colors was primarily due to higher volumes and selling prices and a favorable product mix, partially offset by higher raw material and manufacturing and other costs.
The higher operating income in Food & Pharmaceutical Colors was due to higher selling prices and volumes, a favorable product mix, and the favorable impact of foreign exchange rates, which increased segment operating income by approximately 1%, partially offset by higher raw material and manufacturing and other costs.
These non-GAAP measures may not be comparable to similarly titled measures used by other companies. 24 Index Twelve Months Ended December 31, (In thousands except per share amounts) 2024 2023 % Change Operating Income (GAAP) $ 191,579 $ 155,023 23.6 % Portfolio Optimization Plan costs – Cost of products sold 1,362 3,135 Portfolio Optimization Plan costs – Selling and administrative expenses 5,269 24,706 Adjusted operating income $ 198,210 $ 182,864 8.4 % Net Earnings (GAAP) $ 124,666 $ 93,394 33.5 % Portfolio Optimization Plan costs, before tax 6,631 27,841 Tax impact of Portfolio Optimization Plan costs (1) (4,156 ) (415 ) Adjusted net earnings $ 127,141 $ 120,820 5.2 % Diluted Earnings Per Share (GAAP) $ 2.94 $ 2.21 33.0 % Portfolio Optimization Plan costs, net of tax 0.06 0.65 Adjusted diluted earnings per share $ 3.00 $ 2.86 4.9 % Operating Income (GAAP) $ 191,579 $ 155,023 23.6 % Depreciation and amortization 60,329 57,820 Share-based compensation expense 10,084 8,933 Portfolio Optimization Plan costs, before tax 6,631 27,841 Adjusted EBITDA $ 268,623 $ 249,617 7.6 % (1) Tax impact adjustments were determined based on the nature of the underlying non-GAAP adjustments and their relevant jurisdictional tax rates.
These non-GAAP measures may not be comparable to similarly titled measures used by other companies. 25 Index Twelve Months Ended December 31, (In thousands except per share amounts) 2025 2024 % Change Operating Income (GAAP) $ 207,128 $ 191,579 8.1 % Portfolio Optimization Plan costs – Cost of products sold 7,531 1,362 Portfolio Optimization Plan costs – Selling and administrative expenses 8,275 5,269 Adjusted operating income $ 222,934 $ 198,210 12.5 % Net Earnings (GAAP) $ 134,489 $ 124,666 7.9 % Portfolio Optimization Plan costs, before tax 15,806 6,631 Tax impact of Portfolio Optimization Plan costs (1) (2,001 ) (4,156 ) Adjusted net earnings $ 148,294 $ 127,141 16.6 % Diluted Earnings Per Share (GAAP) $ 3.16 $ 2.94 7.5 % Portfolio Optimization Plan costs, net of tax 0.32 0.06 Adjusted diluted earnings per share $ 3.48 $ 3.00 16.0 % Operating Income (GAAP) $ 207,128 $ 191,579 8.1 % Depreciation and amortization 61,098 60,329 Share-based compensation expense 13,946 10,084 Portfolio Optimization Plan costs, before tax 15,806 6,631 Adjusted EBITDA $ 297,978 $ 268,623 10.9 % (1) Tax impact adjustments were determined based on the nature of the underlying non-GAAP adjustments and their relevant jurisdictional tax rates.
Segment performance is evaluated on operating income before any applicable share-based compensation, acquisition, restructuring and other costs, including the Portfolio Optimization Plan costs, and other costs (which are reported in Corporate & Other), interest expense, and income taxes.
Segment performance is evaluated on operating income before share-based compensation (except for share-based compensation expense associated with stock grants to certain business unit leaders) , restructuring and other costs, including the Portfolio Optimization Plan costs, and other costs (which are reported in Corporate & Other), interest expense, and income taxes.
There were no shares of Company stock repurchased in 2024 or 2023. Cash Flows from Operating Activities Net cash provided by operating activities was $157.2 million and $169.7 million in 2024 and 2023, respectively. Operating cash flow provided the primary source of funds for operating needs, capital expenditures, and shareholder dividends.
Cash Flows from Operating Activities Net cash provided by operating activities was $127.8 million and $157.2 million in 2025 and 2024, respectively. Operating cash flow provided the primary source of funds for operating needs, capital expenditures, and shareholder dividends.
Cash Flows from Investing Activities Net cash used in investing activities was $59.2 million and $87.6 million in 2024 and 2023, respectively. Capital expenditures were $59.2 million in 2024 and $87.9 million in 2023.
Cash Flows from Investing Activities Net cash used in investing activities was $92.7 million and $59.2 million in 2025 and 2024, respectively. Capital expenditures were $89.4 million in 2025 and $59.2 million in 2024 .
The Company’s corporate expenses, share-based compensation, restructuring and other charges, including the Portfolio Optimization Plan costs, and other costs are included in the “Corporate & Other” category.
The Company’s corporate expenses, share-based compensation (except for share-based compensation expense associated with stock grants to certain business unit leaders) , restructuring and other charges, including the Portfolio Optimization Plan costs, and other costs are included in the “Corporate & Other” category.
The Company had a net decrease in debt of $7.8 million and $3.5 million in 2024 and 2023, respectively. For the purposes of the cash flow statement, net changes in debt exclude the impact of foreign exchange rates. The Company has paid uninterrupted quarterly cash dividends since commencing public trading of its stock in 1962.
For the purposes of the cash flow statement, net changes in debt exclude the impact of foreign exchange rates. The Company has paid uninterrupted quarterly cash dividends since commencing public trading of its stock in 1962. Dividends paid per share were $1.64 in 2025 and 2024. Total dividends paid were $69.6 million and $69.4 million in 2025 and 2024, respectively.
The Company believes that it has the ability to refinance or repay all of its obligations through a combination of cash flow from operations, issuance of additional notes, and substantial borrowing capacity of approximately $257 million under the Company’s revolving credit facility, which matures in 2026. 26 Index As a result of our ability to manage the impact of inflation through pricing and other actions, the impact of inflation was not material to the Company’s financial position and its results of operations in 2024.
The Company believes that it has the ability to refinance or repay all of its obligations through a combination of cash flow from operations, issuance of additional notes, and substantial borrowing capacity of approximately $261 million under the Company’s revolving credit facility, which matures in 2030.
The increase in segment operating income was a result of higher volumes and selling prices, partially offset by higher raw material and manufacturing and other costs and the unfavorable impact of foreign exchange rates, which decreased segment operating income by approximately 2%. Segment operating income as a percent of revenue was 21.2% in 2024 and 21.1% in 2023.
The increase in segment operating income was a result of higher selling prices, a favorable product mix, and the favorable impact of foreign exchange rates, which increased segment operating income by approximately 3%, partially offset by higher raw material and manufacturing and other costs.
Portfolio Optimization Plan During the fourth quarter of 2023, the Board of Directors of the Company approved a plan to undertake an effort to optimize certain production facilities and improve efficiencies within the Company (Portfolio Optimization Plan).
See Note 2, Acquisition , in the Notes to Consolidated Financial Statements included in this report for additional information. Portfolio Optimization Plan During the fourth quarter of 2023, the Board of Directors of the Company approved a plan to undertake an effort to optimize certain production facilities and improve efficiencies within the Company (Portfolio Optimization Plan).
Selling and administrative expenses in 2024 and 2023 were increased by Portfolio Optimization Plan costs totaling $5.3 million and $24.7 million, respectively. Selling and administrative expense as a percent of revenue increased by approximately 40 basis points and 170 basis points in 2024 and 2023, respectively, as a result of these costs. See Portfolio Optimization Plan below for further information.
Selling and administrative expense as a percent of revenue increased by approximately 50 basis points and 40 basis points in 2025 and 2024, respectively, as a result of these costs. See Portfolio Optimization Plan below for further information. Operating Income Operating income was $207.1 million in 2025 and $191.6 million in 2024.
Segment operating income as a percent of revenue was 12.2% and 11.8% for 2024 and 2023, respectively. Color Segment revenue for the Color segment was $647.9 million in 2024 and $608.0 million in 2023, an increase of approximately 7%.
Segment operating income as a percent of revenue was 12.8% and 12.2% for 2025 and 2024, respectively. Color Color segment revenue was $700.6 million in 2025 and $647.9 million in 2024, an increase of approximately 8%. The higher segment revenue was a result of higher revenue in Food & Pharmaceutical Colors and Personal Care.
Asia Pacific Segment revenue for the Asia Pacific segment was $162.5 million and $146.1 million for 2024 and 2023, respectively, an increase of approximately 11%. Segment revenue was higher than the prior year primarily due to higher volumes and selling prices, partially offset by the unfavorable impact of foreign exchange rates, which decreased segment revenue by approximately 2%.
Segment revenue was higher than the prior year primarily due to higher selling prices and the favorable impact of foreign exchange rates, which increased segment revenue by approximately 1%, partially offset by lower volumes largely driven by tariff-related impacts. Asia Pacific segment operating income was $36.6 million in 2025 and $34.5 million in 2024, an increase of approximately 6%.
While significant judgment is involved in determining the net realizable value of certain inventories with shorter expirations, the Company believes that inventory is appropriately stated at the lower of cost or net realizable value.
While significant judgment is involved in determining the net realizable value of certain inventories with shorter expirations, the Company believes that inventory is appropriately stated at the lower of cost or net realizable value. 29 Index Commitments and Contingencies The Company is subject to litigation and other legal proceedings arising in the ordinary course of its businesses or arising under applicable laws and regulations.
Flavors & Extracts Flavors & Extracts segment revenue was $793.7 million in 2024 and $741.1 million in 2023, an increase of approximately 7%. The higher segment revenue was a result of higher revenue in Natural Ingredients and Flavors, Extracts & Flavor Ingredients due to higher volumes and selling prices. Foreign exchange rates had an immaterial impact on segment revenue.
The lower revenue in Agricultural Ingredients was due to lower volumes, partially offset by higher selling prices. The higher revenue in Flavors, Extracts & Flavor Ingredients was primarily due to higher selling prices and volumes. Foreign exchange rates had an immaterial impact on segment revenue.
Gross Profit The Company’s gross margin was 32.6% in 2024 and 31.6% in 2023. The increase in gross margin was primarily due to higher volumes and selling prices, partially offset by higher raw material costs. Selling and Administrative Expenses Selling and administrative expense as a percent of revenue was 20.3% in 2024 and 21.0% in 2023.
Gross Profit The Company’s gross margin was 33.5% in 2025 and 32.6% in 2024. The increase in gross margin was primarily due to higher selling prices and volumes, partially offset by higher raw material costs and higher Portfolio Optimization Plan costs.
When it is probable that the Company has incurred a liability associated with claims or pending or threatened litigation matters and the Company’s exposure is reasonably estimable, the Company records a charge against earnings. The Company recognizes related insurance reimbursement when receipt is deemed probable.
Estimating liabilities and costs associated with these matters requires the judgment of management, who rely in part on information from Company legal counsel. When it is probable that the Company has incurred a liability associated with claims or pending or threatened litigation matters and the Company’s exposure is reasonably estimable, the Company records a charge against earnings.
See Note 15, Portfolio Optimization Plan , in the Notes to Consolidated Financial Statements included in this report for additional information.
The Company has substantially completed all other actions contemplated under the Portfolio Optimization Plan in accordance with local laws. See Note 14, Portfolio Optimization Plan , in the Notes to Consolidated Financial Statements included in this report for additional information.
The higher segment revenue was a result of higher revenue in Food & Pharmaceutical Colors and Personal Care due to higher volumes and selling prices, partially offset by the unfavorable impact of foreign exchange rates, which decreased segment revenue by approximately 1% .
The higher revenue in Food & Pharmaceutical Colors was primarily due to higher volumes and selling prices. The higher revenue in Personal Care was primarily due to higher selling prices and the acquisition of Biolie SAS , partially offset by lower volumes.
The increase in expense was primarily due to an increase in the average interest rate. 23 Index Income Taxes The effective income tax rate was 23.4% in 2024 and 28.1% in 2023.
Additional information on segment results can be found in the Segment Information section. Interest Expense Interest expense was $29.6 million in 2025 and $28.8 million in 2024. The increase in expense was primarily due to an increase in the average outstanding debt balance. 24 Index Income Taxes The effective income tax rate was 24.3% in 2025 and 23.4% in 2024.
Corporate & Other The Corporate & Other operating loss was $59.5 million in 2024 and $68.9 million in 2023. The lower operating loss was primarily a result of lower Portfolio Optimization Plan costs, partially offset by higher performance-based compensation costs in 2024. See the Portfolio Optimization Plan section above for further information.
Segment operating income as a percent of revenue was 21.8% in 2025 and 21.2% in 2024. 27 Index Corporate & Other The Corporate & Other operating loss was $71.5 million in 2025 and $59.5 million in 2024. The higher operating loss was primarily a result of higher Portfolio Optimization Plan costs and higher performance-based compensation costs in 2025.
Segment operating income for the Color segment was $119.5 million in 2024 and $105.4 million in 2023, an increase of approximately 13%. The higher segment operating income was a result of higher operating income in Personal Care and Food & Pharmaceutical Colors.
The higher segment operating income was a result of higher operating income in Food & Pharmaceutical Colors, partially offset by lower operating income in Personal Care.
Segment operating income for the Asia Pacific segment was $34.5 million in 2024 and $30.8 million in 2023, an increase of approximately 12%.
Asia Pacific Asia Pacific segment revenue was $168.2 million and $162.5 million for 2025 and 2024, respectively, an increase of approximately 4%.
The Company’s contractual obligations consist primarily of operational commitments, which we expect to continue to be able to satisfy through cash generated from operations, and debt. The Company has various series of notes outstanding that mature from 2025 through 2029, with approximately $56 million coming due in 2025.
However, the Company anticipates to increase its existing debt capacity over the coming years to further support the increased cash requirements for operations and capital expenditures associated with the natural colors conversion activity. The Company’s contractual obligations consist primarily of operational commitments, which we expect to continue to be able to satisfy through cash generated from operations, and debt.
These increases were partially offset by the unfavorable impact of foreign exchange rates, which decreased segment operating income by approximately 1%. Segment operating income as a percent of revenue was 18.4% and 17.3% for 2024 and 2023, respectively.
Segment revenue was further increased by the favorable impact of foreign exchange rates, which increased segment revenue by a pproximately 1% . Color segment operating income was $141.3 million in 2025 and $119.5 million in 2024, an increase of approximately 18%.
The Company has experienced increased costs for certain inputs, such as raw materials, shipping and logistics, and labor-related costs. We continue to expect to manage these impacts in the near term, but persistent, accelerated, or expanded inflationary conditions could exacerbate these challenges and impact our profitability.
We continue to expect to manage these impacts in the near term, but persistent, accelerated, or expanded inflationary conditions could exacerbate these challenges and impact our profitability. The United States implemented significant tariffs on imports from a wide range of countries in 2025 and has announced the possibility of implementing additional, or increasing current, tariffs in 2026.
Selling and administrative expenses as a percent of revenue was further impacted by higher performance-based compensation costs in 2024. Operating Income Operating income was $191.6 million in 2024 and $155.0 million in 2023. Operating margins were 12.3% in 2024 and 10.6% in 2023.
Selling and Administrative Expenses Selling and administrative expense as a percent of revenue was 20.6% in 2025 and 20.3% in 2024. Selling and administrative expenses in 2025 and 2024 were increased by Portfolio Optimization Plan costs totaling $8.3 million and $5.3 million, respectively.
The Company paid $1.7 million in 2023 related to a purchase price holdback associated with the acquisition of Endemix Doğal Maddeler A.Ş. and Teknoloji Yatırımları ve Danışmanlık Sanayi ve Ticaret A.Ş. Cash Flows from Financing Activities Net cash used in financing activities was $81.5 million and $82.0 million in 2024 and 2023, respectively.
In 2025, the Company paid $4.9 million for the acquisition of Biolie SAS . 28 Index Cash Flows from Financing Activities Net cash used in financing activities was $35.0 million and $81.5 million in 2025 and 2024, respectively.
Portfolio Optimization Plan costs decreased operating margins by approximately 40 basis points and 200 basis points in 2024 and 2023, respectively. Additional information on segment results can be found in the Segment Information section. Interest Expense Interest expense was $28.8 million in 2024 and $25.2 million in 2023.
Operating margins were 12.8% in 2025 and 12.3% in 2024. Portfolio Optimization Plan costs decreased operating margins by approximately 100 basis points and 40 basis points in 2025 and 2024, respectively. Operating margins were positively impacted by the higher selling prices and volumes, partially offset by higher raw material costs.